HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Bolt Biotherapeutics (NASDAQ:BOLT) and maintains an $8 price target.
May 26, 2023 | 10:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Bolt Biotherapeutics and maintains an $8 price target.
The news of HC Wainwright & Co. analyst Edward White reiterating a Buy rating on Bolt Biotherapeutics and maintaining an $8 price target is positive for the company. This reaffirms the analyst's confidence in the company's potential, which could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100